Amgen Inc. (FRA:AMG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 135.21B |
| Revenue (ttm) | 31.57B |
| Net Income (ttm) | 5.49B |
| Shares Out | n/a |
| EPS (ttm) | 10.12 |
| PE Ratio | 24.63 |
| Forward PE | 14.31 |
| Dividend | 8.59 (3.56%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 2 |
| Average Volume | 343 |
| Open | 240.30 |
| Previous Close | 239.05 |
| Day's Range | 238.95 - 241.45 |
| 52-Week Range | 230.75 - 318.05 |
| Beta | n/a |
| RSI | 35.68 |
| Earnings Date | Aug 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Before this week Amgen hasn't been able to generate excitement for its GLP-1, says Jim Cramer
'Mad Money' host Jim Cramer looks into stock movement connected to Amgen's GLP-1 offerings.
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen Inc (NASDAQ: AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcu...
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously a...
What's Happening With Amgen Stock?
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to m...
Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. ... Full story available on Benzinga.com
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.
Amgen falls despite positive weight loss trial results
Low start dose of Amgen experimental weight-loss drug limits side effects
People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-st...
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvement...
Monthly weight loss drug helps people lose 20% of body weight, trial finds
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial.
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions and sleep apnea.
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
Amgen Options Trading: A Deep Dive into Market Sentiment
Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ: AMGN) revealed 14 unusual trades. Delving into the details, we found 35% of traders ...
Amgen to present data from mid-stage obesity study
AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes New Repatha® Data Provide Insight Into the Benefi...
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan
The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.
Amgen: Imdelltra Data And Q1 Results Impress
Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Unpacking the Latest Options Trading Trends in Amgen
High-rolling investors have positioned themselves bearish on Amgen (NASDAQ: AMGN), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tr...
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m.